| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GRIN2D |
| Uniprot No | O15399 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GRIN2D重组蛋白的3篇代表性文献(信息基于公开研究总结，非真实文献)：
1. **文献名称**：*"Recombinant expression and functional characterization of the human NMDA receptor subunit GluN2D (GRIN2D) in HEK293 cells"*
**作者**：Smith A, et al.
**摘要**：该研究报道了利用HEK293细胞系统表达GRIN2D重组蛋白，并与其他NMDA受体亚基(如GluN1)共表达，通过电生理记录验证了重组受体的功能性。研究发现GRIN2D重组受体对谷氨酸和甘氨酸的敏感性显著区别于其他亚型，为靶向药物筛选提供了模型。
2. **文献名称**：*"Structural insights into the GRIN2D NMDA receptor subunit via cryo-EM analysis of a recombinant heterotetrameric complex"*
**作者**：Li X, et al.
**摘要**：作者通过冷冻电镜技术解析了包含GRIN2D的重组NMDA受体四聚体结构，揭示了其跨膜域和配体结合域的独特构象。该研究阐明了GRIN2D在受体门控和钙离子通透性中的作用机制，为神经退行性疾病相关突变提供了结构基础。
3. **文献名称**：*"High-yield purification of recombinant GRIN2D protein for biochemical and biophysical studies"*
**作者**：Chen R, et al.
**摘要**：研究开发了一种高效纯化GRIN2D重组蛋白的方法，利用昆虫细胞表达系统结合亲和层析技术获得高纯度蛋白。通过体外实验验证了其与突触后支架蛋白的相互作用，并分析了磷酸化修饰对其功能的影响。
---
**备注**：以上文献为模拟示例，实际研究中建议通过PubMed、Google Scholar等平台以关键词“GRIN2D recombinant protein”或“GluN2D expression”检索最新文献。如需具体文章，可提供更详细的研究方向(如结构、疾病模型或药物开发)。
**Background of GRIN2D Recombinant Protein**
GRIN2D, also known as GluN2D, encodes the epsilon-4 subunit of the N-methyl-D-aspartate (NMDA) receptor, a subtype of ionotropic glutamate receptors critical for synaptic plasticity, learning, and memory. As a key component of NMDA receptors, GRIN2D forms heterotetrameric complexes with GluN1 subunits, creating ligand-gated ion channels permeable to calcium. These channels require dual agonists (glutamate and glycine) and membrane depolarization to relieve magnesium block, enabling their activation during neuronal signaling.
The GRIN2D subunit is developmentally regulated, with expression peaking early in the brain and persisting in specific regions like the thalamus, hippocampus, and cerebellum. Its unique biophysical properties, such as slower deactivation kinetics and reduced magnesium sensitivity, influence synaptic integration and network oscillations. Dysregulation of GRIN2D is linked to neurological disorders, including epilepsy, intellectual disability, and movement disorders. Gain- or loss-of-function mutations in GRIN2D are increasingly identified as causal factors in pediatric encephalopathies, driving interest in targeted therapeutics.
Recombinant GRIN2D proteins are engineered *in vitro* using systems like HEK293 or insect cells to study receptor structure-function relationships, ligand interactions, and pathogenic mechanisms. These purified proteins enable detailed biochemical assays, cryo-EM studies, and high-throughput drug screening. By expressing GRIN2D with partner subunits, researchers reconstitute functional receptors to explore modulation by allosteric compounds, aiming to develop precision treatments for GRIN2D-related disorders. The use of recombinant GRIN2D has significantly advanced understanding of NMDA receptor diversity and their roles in health and disease.
×
